Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes

Amgen announced new data from the phase III study - BANTING - which showed that its PCSK9 inhibitor, Repatha, significantly reduced bad cholesterol in patients with type II diabetes and hypercholesterolemia already receiving moderate/high-intensity statin therapy.